Every material Form 8-K STANDARD BIOTOOLS INC. has filed with the SEC since September 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Standard BioTools and ARCHIMED announced on November 3, 2026, that ARCHIMED has completed its acquisition of Standard BioTools' Microfluidics business. The business will operate as a standalone company under the name Biomark Scientific. The filing does not disclose the purchase price or any financial effect on Standard BioTools.
Closing announced November 3, 2026, in a joint press release with ARCHIMED (Exhibit 99.1)
Buyer ARCHIMED is an investment firm focused on healthcare industries that manages €15 billion across its funds
Business will operate as Biomark Scientific, with Luke Stewart named Chief Commercial Officer
The filing gives no purchase price, revenue, or earnings figures for the business
Standard BioTools said it has signed a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused on healthcare. The sale is expected to close in approximately 30 days, subject to customary closing conditions, and the business will keep operating as part of the company until then. The filing does not disclose the purchase price or the financial effect of the sale on the company.
Definitive agreement announced October 5, 2026, with ARCHIMED, a healthcare-focused investment firm
Closing expected in approximately 30 days, subject to customary closing conditions
Microfluidics business continues to operate within Standard BioTools until closing
The filing does not disclose the sale price or financial impact
Standard BioTools ended its agreement to sell its mass cytometry business to Multiplex Bio and agreed to sell it to Element Biosystems, a subsidiary of GMT Venture, for $5.5 million in cash. The company agreed to pay Multiplex Bio a $1.5 million termination fee, of which GMT Venture will pay $1.0 million, and says the Element deal increases its net cash position by about $15 million compared with the Multiplex Bio transaction, which the Treeline merger exchange ratio takes into account. Completion still depends on stockholder approval and the pending Treeline merger.
Multiplex Bio purchase agreement terminated on September 30, 2026; the company agreed to pay a $1.5 million termination fee, with GMT Venture paying $1.0 million of it on the company's behalf.
Element purchase price is $5.5 million in cash, on a cash-free and debt-free basis, with no financing condition and a GMT Venture equity commitment letter.
Closing requires stockholder approval and consummation of the Treeline merger; the company expects the Element deal to close by the end of 2026.
If the deal terminates in specified circumstances, the company owes Element a $1.0 million termination fee; expense reimbursements of up to $125,000 each apply if closing misses December 31, 2026 or March 31, 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every STANDARD BIOTOOLS INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →